Dashboard

Dr. Abraham is a general physician and rheumatologist. Her clinical interests include inflammatory arthritis namely psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis.

Dr. Abraham has been a consultant physician at Imperial and is the current Head of Clinical and Scientific strategic planning and process at UCB Celltech, which she joined in 2018 as Medical Director, Head of New Treatment Strategies Immunology.

She is an expert in the early diagnosis and treatment of these conditions. Additionally, she has expertise in treating patients whose disease remains active despite conventional disease modifying medication including biologics. Her clinical research interests help to inform her decision making in helping to tailor and monitor response to treatments using clinical, biochemical and imaging measures

She undertook her medical training in London, Oxford and Cambridge.

She was a Clinical Lecturer at the Kennedy Institute of Rheumatology and undertook her PhD, as a Wellcome Clinical Training Fellow, examining the effect of glucocorticoids on pro-inflammatory intracellular signalling.

Her novel finding was that a Dual Specificity Phosphatase (DUSP1) renders partial glucocorticoid resistance (J Exp Med 2006).

Dr. Abraham has successfully co-supervised MD and clinical PhD students in experimental translational inflammatory arthritis. These students presented their work at international meetings and have been awarded prestigious prizes.

She has been the Rheumatology academic clinical fellow (ACF) lead at Imperial and successfully facilitated the creation of the first ACF in London. She was also Lead for Undergraduate Year 5 Rheumatology education at Imperial and an Arthritis Research UK student mentor.

She has been awarded grants from STeLi for “Patient-centric Education” and “Joint examination and injection simulation education”.

Additionally, she is engaged in a number of Public and Patient engagement initiatives to help understanding the needs and value of biomedical research.

Dr. Abraham is committed to nurturing and supporting future academic rheumatologists and training future clinical rheumatologists to help lead/support clinical research.

Dr Smith is a Medical Director for Europe having joined Theradex® in February 2010.

He has background training in Medical Oncology with 15 years’ clinical practice experience. He is a graduate of the Royal College of Surgeons in Ireland and completed his postgraduate training in St Bartholomew and the Royal Marsden hospital. 

Dr Smith joined the industry with PPD as Lead Medical Director for Oncology (ex-US). His responsibilities at Theradex® include evaluation of the clinical, commercial feasibility and project strategy with clients; protocol development; and selecting and liaising with clinical investigators during the clinical trial progress. He is also responsible for assessing AE and SAEs for selected European studies, commenting and preparing narrative reports for onward reporting to clients, regulatory agencies, investigators and ethics committees as necessary.

Dr Smith is also responsible for medical review of data emerging from clients’ clinical trials and for advising clients on appropriate action to be taken based on the emerging data and to advise on risk management especially risk mitigation.

Dr Smith also has experience in early access patient schemes and advising on integrating market access programs in the product lifecycle development.

Dr Smith is a member of both American Society of Clinical Oncologists and European Society of Medical Oncology.

Dr Christophe Le Tourneau is Head of the Phase I Program Institut Curie, Paris.

Euan gained a first class honours in Molecular Biology followed by a PhD in Medical Genetics from the University of Aberdeen.

In 2000 he joined Prof Hani Gabra and his team at the, then Imperial Cancer Research Fund now Cancer Research UK, unit in Edinburgh as a postdoctoral fellow.

From there he moved to Imperial College in 2003 where he ran the Molecular Therapy Lab within the Ovarian Cancer Action Research Centre. 

Since 2015 he is a Senior Investigator at GlaxoSmithKline.

Eaun is a Honorary Senior Lecturer at Imperial College London.

Dr Ioannis Pandis received a Ph.D. degree in Biological Chemistry from the BSRC “Al. Fleming” Institute in Athens, Greee in 2012.

From 2012, he has been working as a research associate at Imperial College. He is in the Discovery Science Group working on the European Innovatice Medicine Initiative (IMI), eTRIKs project, which is aimed at developing a translational information and knowledge management systems.

His personal interest is the development of bioinformatic applications enabling applied biomedical research, with a particular focus on genome regulation analysis.

Dr Jaume Reventós is the director of the Bellvitge Biomedical Research Institute (Idibell) of the University of Barcelona.

He is the co-founder of Transbiomed and was previously head of the Research Unit in Biomedicine and Translational Oncology at the Vall d’Hebron Research Institute (VHIR).

Reventós founded the VHIR spin-off Transbiomed in 2007 alongside Andreas Doll, Miguel Abal and Raimon Forés. In 2013, the company developed a test for early diagnosis of prostate cancer and began research into biomarkers for ovarian cancer.

Dr Cavallaro is a cell biologist and molecular oncologist interested in the biological mechanisms that underlie cancer development.

With his research group he discovered a novel interaction between the adhesion molecule NCAM and the receptor tyrosine kinase FGFR, introducing the paradigm that a growth factor receptor can be activated by a non-canonical ligand such as an adhesion molecule (Francavilla et al., J Cell Sci, 2007, and J Cell Biol, 2009).

His group also discovered that the NCAM/FGFR interaction plays a causal role in ovarian cancer, where it also emerged as a potential therapeutic target in preclinical models (Zecchini et al., EMBO Mol Med, 2011).

Another adhesion molecule that is intensively studied in his lab is L1, originally described as a neural adhesion molecule. They reported that L1 is expressed in specific lineages of the hematopoietic compartment, where it regulates immune cell motility and trafficking (Maddaluno et al., J Exp Med, 2009). Furthermore, his group reported that L1 plays a dual, cell context-dependent role in ovarian cancer (Zecchini et al, Cancer Res, 2008).

More recently, his research group became interested in the novel, unexpected role of adhesion molecules in tumor angiogenesis and vascular maturation. These observations led them to propose novel therapeutic target for anti-angiogenic treatments.

He is actively addressing these scientific issues in preclinical models and clinical samples of specific tumor types, such as pancreatic and ovarian carcinoma.

Another area of intense research in his group is the identification and characterisation of ovarian cancer stem cells, namely an elusive subset of transformed cells that is is thought to drive cancer development, dissemination, recurrence and chemoresistance.

Finally, they are actively pursuing the definition of novel ovarian cancer biomarkers and potential targets, combining cutting edge technologies with the use of clinically relevant specimens, taking advantage of a close collaboration with IEO gynecological oncologists

Professor Bowtell is the Head of the Cancer Genomics and Genetics Program at Peter MacCallum Cancer Centre and PI for the Australian Ovarian Cancer Study (AOCS).

Professor Bowtell is one of Australia’s leading ovarian cancer and human molecular genetics researchers.

He was Director of Research at Peter Mac for the last decade, returning to fulltime research in 2010 to lead the ovarian cancer arm of the National Health and Medical Research Council’s (NHMRC) $27 million involvement in the International Cancer Genomics Consortium, a world-wide effort aimed at mapping all the significant mutations in common cancers.

 Professor Bowtell heads the Australian Ovarian Cancer Study, a nationally collaborative project involving over 2000 women with ovarian cancer and one of the largest cohort studies of ovarian cancer in the world.

He is a molecular biologist and his lab focuses on the genomic analysis of ovarian cancer, with a focus on primary and acquired drug resistance. His lab is also funded from Cancer Australia and the US DoD to investigate high-risk BRCA mutations in women with ovarian cancer.